Lennox-Gastaut syndrome (LGS) is a severe, pediatric-onset epilepsy syndrome characterized by developmental delay or regression, multiple seizure types, and electroencephalographic abnormalities. LGS patients have a higher mortality rate than age-matched peers, with seizure complications being a prominent contributing factor. Despite the availability of more than 25 antiepileptic drugs (AEDs), several of which are approved specifically to treat LGS, the majority of LGS patients do not attain adequate seizure control even with chronic polypharmacy. Despite the highly genericized nature of the epilepsy market, opportunity exists for novel branded therapies that offer greater efficacy, safety, and tolerability than approved or commonly prescribed LGS treatment options.

Table of contents

  • Epilepsy - Unmet Need - Detailed, Expanded Analysis: Lennox Gastaut Syndrome
    • Treatment Drivers and Goals
      • Overview
      • Physician Rating of Treatment Drivers and Goals in LGS
        • Importance of Efficacy Attributes to Prescribing Decisions in LGS: United States
        • Importance of Efficacy Attributes to Prescribing Decisions in LGS: Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in LGS: United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in LGS: Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in LGS: United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in LGS: Europe
        • Importance of Non-Clinical Factors to Prescribing Decisions in LGS: United States
        • Importance of Non-Clinical Factors to Prescribing Decisions in LGS: Europe
      • Stated Versus Derived Importance of Treatment Drivers and Goals
        • Stated Versus Derived Importance of Key Treatment Drivers and Goals
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Attributes to Prescribing Decisions in LGS: United States
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Attributes to Prescribing Decisions in LGS: Europe
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
        • Products for LGS
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Overall Performance of Key Therapies for LGS: United States
        • Overall Performance of Key Therapies for LGS: Europe
        • Relative Performance of Key Therapies for LGS Across Select Efficacy Attributes: United States
        • Relative Performance of Key Therapies for LGS Across Select Efficacy Attributes: Europe
        • Relative Performance of Key Therapies for LGS Across Select Safety and Tolerability Attributes: United States
        • Relative Performance of Key Therapies for LGS Across Select Safety and Tolerability Attributes: Europe
        • Relative Performance of Key Therapies for LGS Across Select Convenience of Administration Attributes: United States
        • Relative Performance of Key Therapies for LGS Across Select Convenience of Administration Attributes: Europe
        • Relative Performance of Key Therapies for LGS Across Select Non-Clinical Attributes: United States
        • Relative Performance of Key Therapies for LGS Across Select Non-Clinical Attributes: Europe
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
        • Surveyed Neurologists' Satisfaction with the Performance of Key Therapies for LGS on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors: United States
        • Surveyed Neurologists' Satisfaction with the Performance of Key Therapies for LGS on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors: Europe
      • Physician Rating of Unmet Need in LGS
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in LGS: United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in LGS: Europe
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in LGS: United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in LGS: Europe
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in LGS: United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in LGS: Europe
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Non-Clinical Factors in LGS: United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Non-Clinical Factors in LGS: Europe
      • Unmet Need in LGS and Related Indications
        • Surveyed Neurologists' Ascribed Level of Unmet Need in LGS and Related Indications: United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need in LGS and Related Indications: Europe
    • Opportunity Analysis
      • Areas of Opportunity in the LGS Market and Emerging Therapy Insights
        • Opportunity: A Novel Agent with Greater Efficacy in Preventing Drop Seizures
        • Opportunity: A Novel Agent with Broad-Spectrum Efficacy in Treating Generalized Seizures
        • Opportunity: An Effective Agent for LGS That Is Better Tolerated Than Current Options
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
      • Attribute Importance and Part-Worth Utilities
        • LGS Target Product Profile: Attribute Importance
        • LGS Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • LGS Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • LGS Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • LGS Market Simulations: Target Product Profiles Included in Scenario 1
        • LGS Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • LGS Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • LGS Market Simulations: Target Product Profiles Included in Scenario 2

Author(s): John Crowley; Bethany Christmann, PhD

John leads DRG’s Infectious, Niche, & Rare Diseases team and manages the market research portfolio across niche and rare diseases, anti-infectives, and vaccines. Prior to his current role, he was a Director on the team overseeing syndicated and custom work on niche and rare disease markets, as well as atopic dermatitis content in DRG’s Dermatology portfolio. He also served as a DRG analyst in the neurology space, focused mainly on the multiple sclerosis market. John holds a Ph.D. from the University of Massachusetts Medical School and a Bachelor’s degree from Worcester Polytechnic Institute.

Bethany Christmann, Ph.D., has been with DRG since 2015, and is a Senior Business Insights Analyst with the Central Nervous System/Ophthalmology team. In this role, she covers the neurology space, specializing in Parkinson’s disease and epilepsy; she provides expert insight and authors primary market research and forecasting content focused on these and other neurology indications. Prior to joining DRG, Bethany earned her Ph.D. in neuroscience from Brandeis University, where she studied the cellular interactions involved in memory consolidation and their link to sleep behavior.


Related Reports

Epilepsy - Landscape & Forecast - Disease Landscape & Forecast

Epilepsy, which afflicts approximately 4.7 million people in the major pharmaceutical markets under study according to DRG epidemiology, is a heterogen...

View Details

Epilepsy | Disease Landscape and Forecast | G7 | 2020

Epilepsy, which afflicts approximately 4.7 million people in the major markets according to DRG epidemiology, is a heterogeneous condition requiring individualized treatment based largely on a...

View Details

Epilepsy - Special Topics - Epilepsy Special Topics New Treatments In Epilepsy US

More than two dozen antiepileptic drugs (AEDs) are available in the United States, yet approximately one-third of epilepsy patients are refractory to

View Details